Adenosine receptor signalling as a driver of pulmonary fibrosis.


Journal

Pharmacology & therapeutics
ISSN: 1879-016X
Titre abrégé: Pharmacol Ther
Pays: England
ID NLM: 7905840

Informations de publication

Date de publication:
09 2023
Historique:
received: 17 03 2023
revised: 30 06 2023
accepted: 20 07 2023
medline: 28 8 2023
pubmed: 24 7 2023
entrez: 23 7 2023
Statut: ppublish

Résumé

Pulmonary fibrosis is a debilitating and life-limiting lung condition in which the damage- response mechanisms of mixed-population cells within the lungs go awry. The tissue microenvironment is drastically remodelled by aberrantly activated fibroblasts which deposit ECM components into the surrounding lung tissue, detrimentally affecting lung function and capacity for gas exchange. Growing evidence suggests a role for adenosine signalling in the pathology of tissue fibrosis in a variety of organs, including the lung, but the molecular pathways through which this occurs remain largely unknown. This review explores the role of adenosine in fibrosis and evaluates the contribution of the different adenosine receptors to fibrogenesis. Therapeutic targeting of the adenosine receptors is also considered, along with clinical observations pointing towards a role for adenosine in fibrosis. In addition, the interaction between adenosine signalling and other profibrotic signalling pathways, such as TGFβ1 signalling, is discussed.

Identifiants

pubmed: 37482099
pii: S0163-7258(23)00168-7
doi: 10.1016/j.pharmthera.2023.108504
pii:
doi:

Substances chimiques

Adenosine K72T3FS567
Receptors, Purinergic P1 0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

108504

Subventions

Organisme : Wellcome Trust
ID : UNS146151
Pays : United Kingdom
Organisme : Department of Health
ID : CL-2020-12-003
Pays : United Kingdom

Informations de copyright

Copyright © 2023 University of Nottingham. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Emily Cash reports financial support was provided by Wellcome Trust. Amanda TAtler reports a relationship with Accession Therapeutics Limited that includes: consulting or advisory. Amanda Tatler reports a relationship with ELSEVIER INC that includes: board membership. Amanda Tatler reports a relationship with Pliant Therapeutics Inc. that includes: consulting or advisory.

Auteurs

Emily Cash (E)

Centre for Respiratory Research, Translational Medical Sciences, School of Medicine, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK.

Amanda T Goodwin (AT)

Centre for Respiratory Research, Translational Medical Sciences, School of Medicine, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK.

Amanda L Tatler (AL)

Centre for Respiratory Research, Translational Medical Sciences, School of Medicine, University of Nottingham, UK; NIHR Nottingham Biomedical Research Centre, Nottingham, UK. Electronic address: amanda.tatler@nottingham.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH